A2i Therapeutics Ltd.
Biomed — Stage: R&D. Est: 2020. Tags: Artificial Intelligence, Biotechnology, Drug Discovery, Life Sciences, MedTech, Pharmaceuticals. A2i Therapeutics aims to develop novel therapeutic modulators of the protein ADAR1, a key element of the innate immune system. A2i is a joint venture of the FutuRx Incubator and Atomwise, utilizing the AtomNet® AI platform and FutuRx’s drug development capabilities to develop proprietary therapeutic candidates for Immun-oncology and autoimmune indications.. Web: https://a2i-tx.com